Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer
- 1 January 2015
- book chapter
- Published by Springer Nature
- Vol. 867, 293-316
Abstract
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words “cisplatin”, “bladder cancer”, “DNA marker”, “protein marker”, “methylation biomarker”, “predictive marker”, “prognostic marker” has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.Keywords
This publication has 114 references indexed in Scilit:
- Adseverin: A novel cisplatin‐resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysisMolecular Oncology, 2012
- Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancerBMC Cancer, 2011
- Excision repair cross‐complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin‐based chemotherapyAPMIS, 2010
- Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expressionMolecular Cancer, 2010
- Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin‐based chemoradiationInternational Journal of Cancer, 2009
- Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapyAnnals of Oncology, 2007
- HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implicationsInternational Journal of Cancer, 2002
- Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tractJournal of Cancer Research and Clinical Oncology, 1992
- METALLOTHIONEINAnnual Review of Biochemistry, 1986
- Prognostic Significance of Serum CRP Levels and Lymphoid Cell Infiltrates in Human Breast CancerOncology, 1982